Join to access to all OVN content. Join for Free
Prepare to LAUNCH: How to Build an MSL Team From Scratch
MSL team building drug launch strategy medical science liaison recruitment field medical team best practices MSL training phases

Prepare to LAUNCH: How to Build an MSL Team From Scratch


Share This Article


Summary

In episode 152, Tom Caravela is joined by John Caskey to delve into the intricacies of assembling the ideal MSL team for a successful drug launch. The discussion covers strategic timing, the importance of leadership, and the sequence of hiring MSLs. Operational requirements such as team size, territory allocation, and KOL support management are explored, alongside the recruiting timeline. The episode highlights key skills and criteria essential for selecting MSLs and emphasizes the need for comprehensive training, detailing how to balance different training phases. The conversation wraps up with a summary of best practices for building an effective field medical team.

Tom Caravela, Managing Partner at The Carolan Group and Host of the MSL Talk Podcast, is interviewed by Jon Kaskey on how to build an MSL team in preparation for a drug launch.
Tom shares….

πŸ‘‰ How early should companies consider hiring MSLs
πŸ‘‰ Who spearheads the process for building out the team
πŸ‘‰ What factors go into determining the number of MSLs per team
πŸ‘‰ How are territories aligned and allocated
πŸ‘‰ What other factors need to be considered for internal medical affairs preparedness

Click for Source
MSL team building, drug launch strategy, medical science liaison recruitment, field medical team best practices, MSL training phases

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN